Swedish Orphan Biovitrum AB (publ) Stock Forecast, Price & News

-1.10 (-5.54 %)
(As of 06/16/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume126 shs
Average Volume759 shs
Market Capitalization$5.62 billion
P/E Ratio17.36
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BIOVF News and Ratings via Email

Sign-up to receive the latest news and ratings for Swedish Orphan Biovitrum AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

Swedish Orphan Biovitrum AB (publ) logo

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.87 out of 5 stars

Medical Sector

1200th out of 2,102 stocks

Analyst Opinion: 0.0Community Rank: 1.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 3.1 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Frequently Asked Questions

Is Swedish Orphan Biovitrum AB (publ) a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Swedish Orphan Biovitrum AB (publ) in the last twelve months. There are currently 6 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Swedish Orphan Biovitrum AB (publ) stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIOVF, but not buy additional shares or sell existing shares.
View analyst ratings for Swedish Orphan Biovitrum AB (publ)
or view top-rated stocks.

What stocks does MarketBeat like better than Swedish Orphan Biovitrum AB (publ)?

Wall Street analysts have given Swedish Orphan Biovitrum AB (publ) a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Swedish Orphan Biovitrum AB (publ) wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Swedish Orphan Biovitrum AB (publ)'s next earnings date?

Swedish Orphan Biovitrum AB (publ) is scheduled to release its next quarterly earnings announcement on Thursday, July 15th 2021.
View our earnings forecast for Swedish Orphan Biovitrum AB (publ)

How were Swedish Orphan Biovitrum AB (publ)'s earnings last quarter?

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) announced its quarterly earnings data on Tuesday, May, 4th. The company reported $0.28 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.31 by $0.03. The company had revenue of $436.23 million for the quarter, compared to analysts' expectations of $450 million. Swedish Orphan Biovitrum AB (publ) had a net margin of 19.63% and a trailing twelve-month return on equity of 12.50%.
View Swedish Orphan Biovitrum AB (publ)'s earnings history

How has Swedish Orphan Biovitrum AB (publ)'s stock been impacted by COVID-19 (Coronavirus)?

Swedish Orphan Biovitrum AB (publ)'s stock was trading at $20.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BIOVF shares have decreased by 6.3% and is now trading at $18.75.
View which stocks have been most impacted by COVID-19

Who are Swedish Orphan Biovitrum AB (publ)'s key executives?

Swedish Orphan Biovitrum AB (publ)'s management team includes the following people:
  • Dr. Guido Oelkers, CEO & Pres (Age 56)
  • Mr. Henrik Stenqvist, Chief Financial Officer (Age 54)
  • Dr. Ravi Madduri Rao M.D., Ph.D., Head of R&D and Chief Medical Officer (Age 54)
  • Ms. Anne Marie de Jonge Schuermans, Head of Technical Operations (Age 49)
  • Ms. Paula Treutiger, Head of Corp. Communications & Investor Relations (Age 54)
  • Mr. Torbjörn Hallberg, Gen. Counsel and Head of Legal Affairs & HR (Age 52)
  • Ms. Annika Muskantor, Head of Global Supply Chain (Age 55)
  • Mr. Jorgen L. Winroth, Sr. IR Advisor
  • Mr. Philip Wood, Head of Haematology (Age 53)
  • Mr. Bruce Faulkner-Dunkley, Global Head of L&OD

Who are some of Swedish Orphan Biovitrum AB (publ)'s key competitors?

What is Swedish Orphan Biovitrum AB (publ)'s stock symbol?

Swedish Orphan Biovitrum AB (publ) trades on the OTCMKTS under the ticker symbol "BIOVF."

How do I buy shares of Swedish Orphan Biovitrum AB (publ)?

Shares of BIOVF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Swedish Orphan Biovitrum AB (publ)'s stock price today?

One share of BIOVF stock can currently be purchased for approximately $18.75.

How much money does Swedish Orphan Biovitrum AB (publ) make?

Swedish Orphan Biovitrum AB (publ) has a market capitalization of $5.62 billion and generates $1.66 billion in revenue each year. The company earns $353.70 million in net income (profit) each year or $1.04 on an earnings per share basis.

How many employees does Swedish Orphan Biovitrum AB (publ) have?

Swedish Orphan Biovitrum AB (publ) employs 1,509 workers across the globe.

What is Swedish Orphan Biovitrum AB (publ)'s official website?

The official website for Swedish Orphan Biovitrum AB (publ) is www.sobi.com.

Where are Swedish Orphan Biovitrum AB (publ)'s headquarters?

Swedish Orphan Biovitrum AB (publ) is headquartered at Tomtebodavagen 23 A Solna, Stockholm V7, SE-112 76.

How can I contact Swedish Orphan Biovitrum AB (publ)?

Swedish Orphan Biovitrum AB (publ)'s mailing address is Tomtebodavagen 23 A Solna, Stockholm V7, SE-112 76. The company can be reached via phone at 46-8697-2000 or via email at [email protected]

This page was last updated on 6/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.